Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice
Multiple myeloma is an incurable malignancy of plasma B-cells. Traditional chemotherapeutic regimes often induce initial tumor regression; however, virtually all patients eventually succumb to relapse caused by either reintroduction of disease during autologous transplant or expansion of chemotherap...
Main Authors: | Eric Bartee, Mee Y Bartee, Bjarne Bogen, Xue-Zhong Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Oncolytics |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770517300165 |
Similar Items
-
Potential of oncolytic viruses in the treatment of multiple myeloma
by: Bartee E
Published: (2018-02-01) -
Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus
by: Burton C, et al.
Published: (2019-12-01) -
Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy
by: Erica B. Flores, et al.
Published: (2020-12-01) -
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor–resistant multiple myeloma
by: Dunlap KM, et al.
Published: (2015-01-01) -
Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme
by: Burton C, et al.
Published: (2018-11-01)